Clinical Trials in the EU / 2024-519493-39-00
Authorised, recruiting
Phase III
A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator’s Choice of Intravesical Chemotherapy in Participants with High-risk Non-muscle-invasive Bladder Cancer with Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Guérin (BCG)
2024-519493-39-00 · tracked via the Priya Life Science EU tracker
Condition studied
High-risk Non-muscle-invasive Bladder Cancer with Susceptible FGFR Alterations
Investigational medicinal product(s)
JNJ-42756493MITOMYCINGEMCITABINE
Eligibility
Primary endpoint
DFS
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View 2024-519493-39-00 on CTIS ↗ ← All trials in the EU